Immatics today announced that it has initiated enrollment of patients into a Phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program.
by eazee-designstudio
RIG-GING AN EXIT: Rigontec takeout gives Wellington quick exit, momentum into new Fund.
MSD today announced the acquisition of Rigontec for up to US$553M
The further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio. GBP by the United Kingdom's innovation agency, Innovate UK. Themis will use these funds to identify and validate a correlate of protection for its prophylactic Chikungunya vaccination candidate.
